Brought to you by 
Ocular Therapeutix brings in $14mm through its Series D round; adds money
29 Jan 2013
Executive Summary
Ocular Therapeutix Inc. (focused on the delivery of ophthalmic drugs using hydrogel technology) has raised $14mm through its Series D venture round. New investor Ascension Health Ventures led and was joined by current shareholders including Polaris Ventures, SV Life Sciences, and Versant Ventures. The company will use the proceeds for Phase II trials of its sustained drug delivery system--a moxifloxacin-loaded punctum plug--later this year to reinforce safety and test efficacy, and to study the punctum plugs in the future for glaucoma, dry eye, and allergies.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Medical Devices
- Biomaterials
-
Surgical Equipment & Devices
- Surgical Sealants
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ocular Therapeutix brings in $14mm through its Series D round; adds money
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice